J
John Sweetenham
Researcher at Cleveland Clinic
Publications - 103
Citations - 4365
John Sweetenham is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 26, co-authored 91 publications receiving 4034 citations. Previous affiliations of John Sweetenham include Nevada Cancer Institute & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg,Jeff P. Sharman,John Sweetenham,Patrick B. Johnston,Julie M. Vose,Ann S. LaCasce,Julia Schaefer-Cutillo,Sven de Vos,Rajni Sinha,John P. Leonard,Larry D. Cripe,Stephanie A. Gregory,Michael P. Sterba,Ann M. Lowe,Ronald Levy,Margaret A. Shipp +15 more
TL;DR: Disrupting BCR-induced signaling by inhibiting Syk represents a novel and active therapeutic approach for NHL and SLL/CLL.
Journal ArticleDOI
Enteropathy-Type Intestinal T-Cell Lymphoma: Clinical Features and Treatment of 31 Patients in a Single Center
TL;DR: The prognosis for these patients with a diagnosis of enteropathy-type intestinal T-cell lymphoma treated at the Wessex Regional Medical Oncology Unit in Southampton between 1979 and 1996 is poor; it is encouraging that there are five long-term survivors.
Journal ArticleDOI
Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
Peter Hoskin,Lisa Lowry,Alan Horwich,Andrew Jack,Ben Mead,Barry W. Hancock,Paul Smith,Wendi Qian,Philippa Patrick,Bilyana Popova,Andrew R. Pettitt,David Cunningham,Ruth Pettengell,John Sweetenham,David C. Linch,Peter Johnson +15 more
TL;DR: In a large, randomized trial, the efficacies of Stanford V and ABVD were comparable when given in combination with appropriate radiotherapy.
Journal ArticleDOI
Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation.
Anuj Mahindra,Brian J. Bolwell,Ronald Sobecks,Lisa Rybicki,Brad Pohlman,Robert M. Dean,Steve Andresen,John Sweetenham,Matt Kalaycio,Edward A. Copelan +9 more
TL;DR: The results indicate that an elevated pretransplant ferritin level adversely impacts transplantation outcomes and the adverse impact of elevatedferritin on NRM and survival was despite its association with lower incidences of acute and chronic GVHD, which are major causes of NRM.